These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18076216)

  • 21. Ceftobiprole: a new broad spectrum cephalosporin.
    El Solh A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.
    Steed ME; Rybak MJ
    Pharmacotherapy; 2010 Apr; 30(4):375-89. PubMed ID: 20334458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018.
    Flamm RK; Duncan LR; Hamed KA; Smart JI; Mendes RE; Pfaller MA
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftaroline: a new broad-spectrum cephalosporin.
    Lim L; Sutton E; Brown J
    Am J Health Syst Pharm; 2011 Mar; 68(6):491-8. PubMed ID: 21378297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
    Horn KS; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.
    Bush K; Heep M; Macielag MJ; Noel GJ
    Expert Opin Investig Drugs; 2007 Apr; 16(4):419-29. PubMed ID: 17371191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
    Noel GJ; Strauss RS; Amsler K; Heep M; Pypstra R; Solomkin JS
    Antimicrob Agents Chemother; 2008 Jan; 52(1):37-44. PubMed ID: 17954698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
    Schirmer PL; Deresinski SC
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):777-91. PubMed ID: 19735220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).
    Pfaller MA; Flamm RK; Duncan LR; Shortridge D; Smart JI; Hamed KA; Mendes RE; Sader HS
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):304-313. PubMed ID: 30808530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
    Lodise TP; Patel N; Renaud-Mutart A; Gorodecky E; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):96-102. PubMed ID: 18384996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftobiprole medocaril for the treatment of pneumonia.
    Hsu WH; Hsu CK; Lai CC
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):551-563. PubMed ID: 37042813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftobiprole - a case study.
    Page MG
    Expert Opin Drug Discov; 2007 Jan; 2(1):115-29. PubMed ID: 23496040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
    Moreillon P
    Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():32-41. PubMed ID: 18318877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
    Rubino CM; Polak M; Schröpf S; Münch HG; Smits A; Cossey V; Tomasik T; Kwinta P; Snariene R; Liubsys A; Gardovska D; Hornik CD; Bosheva M; Ruehle C; Litherland K; Hamed K
    Pediatr Infect Dis J; 2021 Nov; 40(11):997-1003. PubMed ID: 34533489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.
    Barbour A; Derendorf H
    Ther Clin Risk Manag; 2010 Oct; 6():485-95. PubMed ID: 20957140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of action and antimicrobial activity of ceftobiprole.
    Morosini MI; Díez-Aguilar M; Cantón R
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):3-10. PubMed ID: 31364335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020.
    Duncan LR; Hamed KA; Smart JI; Pfaller MA; Flamm RK; Mendes RE
    Diagn Microbiol Infect Dis; 2022 Jul; 103(3):115713. PubMed ID: 35598410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.